TAK-583

Takeda · Phase 2 active Small molecule

At a glance

Generic name	TAK-583
Sponsor	Takeda
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy (PHASE2)
Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TAK-583 CI brief — competitive landscape report
TAK-583 updates RSS · CI watch RSS
Takeda portfolio CI